Robert Hayes has been appointed chief scientific officer of Seattle-based Immusoft. Hayes joins the cell therapy developer from Phylogica, where he was chief scientific officer for the past two years. His experience also includes positions at Amgen (NASDAQ: [[ticker:AMGN]]) and Johnson & Johnson (NYSE: [[ticker:JNJ]]). Immusoft, which is developing therapies based on modifying a patient’s B cells, raised $20 million in Series B financing earlier this year.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
